发布求助
文献互助 智能选刊 最新文献

Seminars in liver disease最新文献

筛选
英文 中文
Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease. 为 MASLD 患者量身定制的护理模式。
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-01-25 DOI: 10.1055/a-2253-9181
Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab
{"title":"Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.","authors":"Mohamed El-Kassas, Abeer Awad, Mohamed Elbadry, Juan Pablo Arab","doi":"10.1055/a-2253-9181","DOIUrl":"10.1055/a-2253-9181","url":null,"abstract":"<p><p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is increasing globally, creating a growing public health concern. However, this disease is often not diagnosed, and accurate data on its epidemiology are limited in many geographical regions, making it challenging to provide proper care and implement effective national plans. To combat the increasing disease burden, screening and diagnosis must reach a significant number of high-risk subjects. Addressing MASLD as a health care challenge requires a multidisciplinary approach involving prevention, diagnosis, treatment, and care, with collaboration between multiple stakeholders in the health care system. This approach must be guided by national and global strategies, to be combined with efficient models of care developed through a bottom-up process. This review article highlights the pillars of the MASLD model of care (MoC), including screening, risk stratification, and establishing a clinical care pathway for management, in addition to discussing the impact of nomenclature change on the proposed MoC.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"54-68"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139565004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future. 更正：肝细胞癌肝移植：叙事回顾与未来一瞥》。
IF 4.3 3区 医学
Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-06-05 DOI: 10.1055/s-0044-1787737
Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar
{"title":"Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.","authors":"Hao Liu, Vrishketan Sethi, Xingjie Li, Yao Xiao, Abhinav Humar","doi":"10.1055/s-0044-1787737","DOIUrl":"10.1055/s-0044-1787737","url":null,"abstract":"","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"44 1","pages":"e1-e3"},"PeriodicalIF":4.3,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141262894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gestational and Developmental Contributors of Pediatric MASLD. 小儿 MASLD 的妊娠和发育因素。
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-02-29 DOI: 10.1055/s-0044-1782210
Marialena Mouzaki, Jessica G Woo, Senad Divanovic
{"title":"Gestational and Developmental Contributors of Pediatric MASLD.","authors":"Marialena Mouzaki, Jessica G Woo, Senad Divanovic","doi":"10.1055/s-0044-1782210","DOIUrl":"10.1055/s-0044-1782210","url":null,"abstract":"<p><p>Pediatric metabolic dysfunction-associated steatotic liver disease (MASLD) is common and can be seen as early as <i>in utero</i>. A growing body of literature suggests that gestational and early life exposures modify the risk of MASLD development in children. These include maternal risk factors, such as poor cardiometabolic health (e.g., obesity, gestational diabetes, rapid weight gain during pregnancy, and MASLD), as well as periconceptional dietary exposures, degree of physical activity, intestinal microbiome, and smoking. Paternal factors, such as diet and obesity, also appear to play a role. Beyond gestation, early life dietary exposures, as well as the rate of infant weight gain, may further modify the risk of future MASLD development. The mechanisms linking parental health and environmental exposures to pediatric MASLD are complex and not entirely understood. In conclusion, investigating gestational and developmental contributors to MASLD is critical and may identify future interventional targets for disease prevention.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"43-53"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139997392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting. 基层医疗机构早期检测隐匿性肝纤维化的算法。
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-01-23 DOI: 10.1055/s-0043-1778127
Katrine Tholstrup Bech, Katrine Prier Lindvig, Maja Thiele, Laurent Castera
{"title":"Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting.","authors":"Katrine Tholstrup Bech, Katrine Prier Lindvig, Maja Thiele, Laurent Castera","doi":"10.1055/s-0043-1778127","DOIUrl":"10.1055/s-0043-1778127","url":null,"abstract":"<p><p>More than one-third of the adult world population has steatotic liver disease (SLD), with a few percent of individuals developing cirrhosis after decades of silent liver fibrosis accumulation. Lack of systematic early detection causes most patients to be diagnosed late, after decompensation, when treatment has limited effect and survival is poor. Unfortunately, no isolated screening test in primary care can sufficiently predict advanced fibrosis from SLD. Recent efforts, therefore, combine several parameters into screening algorithms, to increase diagnostic accuracy. Besides patient selection, for example, by specific characteristics, algorithms include nonpatented or patented blood tests and liver stiffness measurements using elastography-based techniques. Algorithms can be composed as a set of sequential tests, as recommended by most guidelines on primary care pathways. Future use of algorithms that are easy to interpret, cheap, and semiautomatic will improve the management of patients with SLD, to the benefit of global health care systems.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"23-34"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139542906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GAS6/TAM Axis as Therapeutic Target in Liver Diseases. 作为肝病治疗靶点的 GAS6/TAM 轴。
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2024-02-01 Epub Date: 2024-02-23 DOI: 10.1055/a-2275-0408
Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí
{"title":"GAS6/TAM Axis as Therapeutic Target in Liver Diseases.","authors":"Anna Tutusaus, Albert Morales, Pablo García de Frutos, Montserrat Marí","doi":"10.1055/a-2275-0408","DOIUrl":"10.1055/a-2275-0408","url":null,"abstract":"<p><p>TAM (TYRO3, AXL, and MERTK) protein tyrosine kinase membrane receptors and their vitamin K-dependent ligands GAS6 and protein S (PROS) are well-known players in tumor biology and autoimmune diseases. In contrast, TAM regulation of fibrogenesis and the inflammation mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, and, ultimately, liver cancer has recently been revealed. GAS6 and PROS binding to phosphatidylserine exposed in outer membranes of apoptotic cells links TAMs, particularly MERTK, with hepatocellular damage. In addition, AXL and MERTK regulate the development of liver fibrosis and inflammation in chronic liver diseases. Acute hepatic injury is also mediated by the TAM system, as recent data regarding acetaminophen toxicity and acute-on-chronic liver failure have uncovered. Soluble TAM-related proteins, mainly released from activated macrophages and hepatic stellate cells after hepatic deterioration, are proposed as early serum markers for disease progression. In conclusion, the TAM system is becoming an interesting pharmacological target in liver pathology and a focus of future biomedical research in this field.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"99-114"},"PeriodicalIF":4.2,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139940678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Inhibitor-Induced Liver Injury 免疫检查点抑制剂诱发的肝损伤
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2023-12-15 DOI: 10.1055/s-0043-1776761
Cathrin L.C. Gudd, Roosey Sheth, Mark R. Thursz, Evangelos Triantafyllou, Lucia A. Possamai
{"title":"Immune Checkpoint Inhibitor-Induced Liver Injury","authors":"Cathrin L.C. Gudd, Roosey Sheth, Mark R. Thursz, Evangelos Triantafyllou, Lucia A. Possamai","doi":"10.1055/s-0043-1776761","DOIUrl":"https://doi.org/10.1055/s-0043-1776761","url":null,"abstract":"<p>In recent years cancer treatment has been revolutionized by the development and wide application of checkpoint inhibitor (CPI) drugs, which are a form of immunotherapy. CPI treatment is associated with immune-related adverse events, off-target tissue destructive inflammatory complications, which may affect a range of organs, with liver inflammation (hepatitis) being one of the more commonly noted events. This is a novel form of drug-induced liver injury and a rapidly evolving field, as our understanding of both the basic immunopathology of CPI hepatitis (CPI-H) and optimal clinical management, races to catch up with the increasing application of this form of immunotherapy in clinical practice. In this review, we summarize current evidence and understanding of CPI-H, from fundamental immunology to practical patient management.</p> ","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"33 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138687912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure 治疗急性慢性肝衰竭的新疗法
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2023-12-15 DOI: 10.1055/s-0043-1776773
MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan
{"title":"Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure","authors":"MohammadMahdi Saeidinejad, Ahmed Elshabrawi, Supachaya Sriphoosanaphan, Fausto Andreola, Gautam Mehta, Banwari Agarwal, Rajiv Jalan","doi":"10.1055/s-0043-1776773","DOIUrl":"https://doi.org/10.1055/s-0043-1776773","url":null,"abstract":"<p>Acute-on-chronic liver failure (ACLF), a clinical syndrome that can develop at any stage in the progression of cirrhotic liver disease, is characterized by an acute decompensation in liver function with associated multiorgan failure and high short-term mortality. Current evidence points to ACLF being reversible, particularly in those at the lower end of the severity spectrum. However, there are no specific treatments for ACLF, and overall outcomes remain poor. Expedited liver transplantation as a treatment option is limited by organ shortage and a lack of priority allocation for this indication. Other options are therefore urgently needed, and our improved understanding of the condition has led to significant efforts to develop novel therapies. In conclusion, this review aims to summarize the current understanding of the pathophysiological processes involved in the onset, progression, and recovery of ACLF and discuss novel therapies under development.</p> ","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":"49 1","pages":""},"PeriodicalIF":4.2,"publicationDate":"2023-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138688351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Ploidy State as a Determinant of Hepatocyte Proliferation. 倍性状态是肝细胞增殖的决定因素。
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-11-15 DOI: 10.1055/a-2211-2144
Sierra R Wilson, Andrew W Duncan
{"title":"The Ploidy State as a Determinant of Hepatocyte Proliferation.","authors":"Sierra R Wilson, Andrew W Duncan","doi":"10.1055/a-2211-2144","DOIUrl":"10.1055/a-2211-2144","url":null,"abstract":"<p><p>The liver's unique chromosomal variations, including polyploidy and aneuploidy, influence hepatocyte identity and function. Among the most well-studied mammalian polyploid cells, hepatocytes exhibit a dynamic interplay between diploid and polyploid states. The ploidy state is dynamic as hepatocytes move through the \"ploidy conveyor,\" undergoing ploidy reversal and re-polyploidization during proliferation. Both diploid and polyploid hepatocytes actively contribute to proliferation, with diploids demonstrating an enhanced proliferative capacity. This enhanced potential positions diploid hepatocytes as primary drivers of liver proliferation in multiple contexts, including homeostasis, regeneration and repopulation, compensatory proliferation following injury, and oncogenic proliferation. This review discusses the influence of ploidy variations on cellular activity. It presents a model for ploidy-associated hepatocyte proliferation, offering a deeper understanding of liver health and disease with the potential to uncover novel treatment approaches.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"460-471"},"PeriodicalIF":4.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10862383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134649723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hedgehog Signaling: Implications in Liver Pathophysiology. Hedgehog信号传导：肝脏病理生理学的意义。
IF 4.2 3区 医学
Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-10-06 DOI: 10.1055/a-2187-3382
Rajesh Kumar Dutta, JiHye Jun, Kuo Du, Anna Mae Diehl
{"title":"Hedgehog Signaling: Implications in Liver Pathophysiology.","authors":"Rajesh Kumar Dutta, JiHye Jun, Kuo Du, Anna Mae Diehl","doi":"10.1055/a-2187-3382","DOIUrl":"10.1055/a-2187-3382","url":null,"abstract":"<p><p>The purpose of this review is to summarize current knowledge about the role of the Hedgehog signaling pathway in liver homeostasis and disease. Hedgehog is a morphogenic signaling pathway that is active in development. In most healthy tissues, pathway activity is restricted to stem and/or stromal cell compartments, where it enables stem cell self-renewal and tissue homeostasis. Aberrant over-activation of Hedgehog signaling occurs in many cancers, including hepatocellular and cholangio-carcinoma. The pathway is also activated transiently in stromal cells of injured tissues and orchestrates normal wound healing responses, including inflammation, vascular remodeling, and fibrogenesis. In liver, sustained Hedgehog signaling in stromal cells plays a major role in the pathogenesis of cirrhosis. Hedgehog signaling was thought to be silenced in healthy hepatocytes. However, recent studies show that targeted disruption of the pathway in hepatocytes dysregulates lipid, cholesterol, and bile acid metabolism, and promotes hepatic lipotoxicity, insulin resistance, and senescence. Hepatocytes that lack Hedgehog activity also produce a secretome that activates Hedgehog signaling in cholangiocytes and neighboring stromal cells to induce inflammatory and fibrogenic wound healing responses that drive progressive fibrosis. In conclusion, Hedgehog signaling must be precisely controlled in adult liver cells to maintain liver health.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"418-428"},"PeriodicalIF":4.2,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41170492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease. 肝卟啉症:揭示一种罕见疾病的复杂性。
IF 4.3 3区 医学
Seminars in liver disease Pub Date : 2023-11-01 Epub Date: 2023-11-16 DOI: 10.1055/s-0043-1776760
Oluwashanu Balogun, Kari Nejak-Bowen
{"title":"The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease.","authors":"Oluwashanu Balogun, Kari Nejak-Bowen","doi":"10.1055/s-0043-1776760","DOIUrl":"10.1055/s-0043-1776760","url":null,"abstract":"<p><p>The porphyrias are a group of metabolic disorders that are caused by defects in heme biosynthesis pathway enzymes. The result is accumulation of heme precursors, which can cause neurovisceral and/or cutaneous photosensitivity. Liver is commonly either a source or target of excess porphyrins, and porphyria-associated hepatic dysfunction ranges from minor abnormalities to liver failure. In this review, the first of a three-part series, we describe the defects commonly found in each of the eight enzymes involved in heme biosynthesis. We also discuss the pathophysiology of the hepatic porphyrias in detail, covering epidemiology, histopathology, diagnosis, and complications. Cellular consequences of porphyrin accumulation are discussed, with an emphasis on oxidative stress, protein aggregation, hepatocellular cancer, and endothelial dysfunction. Finally, we review current therapies to treat and manage symptoms of hepatic porphyria.</p>","PeriodicalId":21724,"journal":{"name":"Seminars in liver disease","volume":" ","pages":"446-459"},"PeriodicalIF":4.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11256094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136399097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信